

CREATING A POSITIVE LEGACY FROM THE PANDEMIC

Breaking the cycle of panic to neglect
with an 'Always On' approach

14 April 2023, London





Welcome

from the Warden of Rhodes House



Dear attendees,

Welcome to the inaugural hybrid Rhodes Policy Summit. This year the theme is: *Creating a Positive Legacy from the Pandemic*. We will be exploring the important and innovative concept of using an 'Always On' approach to pandemic preparedness - considering what it will take for governments and societies across the world to stay in a state of readiness which would allow for a swift and effective way to combat a future pandemic threat. This Summit comes at a time when the devastating impact of the COVID-19 pandemic is still fresh in our minds, but with a real risk that this opportunity to reflect, take stock of the lessons learnt from the pandemic and prepare better for the future might be missed.

We have been hugely privileged to be able to have the Global Health Security Consortium as a knowledge partner for this event. The depth of experience and expertise gathered together for this Summit demonstrates the passion so many individuals and organisations have for ensuring that lessons learnt during the pandemic are shared globally, embedded in our systems and processes and will enable us to be in the right place to tackle the next time we face a crisis.

The Policy Summit's programming efforts have focused on an interdisciplinary approach, with a wide variety of geographies and sectors represented amongst the speakers and attendees. This bringing together of people across traditional boundaries is something we focus on within the wider work of the Rhodes Trust. It always leads to new ideas and solutions and I am sure that will also be true today.

I particularly want to thank our Rhodes Chair of Trustees, Professor Sir John Bell, for his leadership during the pandemic and his continued commitment to ensuring the world is better prepared. There is no one better qualified to open the Summit today. Warm thanks also go to Philip Ma for his leadership support for this event and his contributions on the programme's Advisory Board. We would also like to acknowledge the rest of our exceptional advisory board led by Professor Sir John Bell: Dr Trevor Mundel, Dr Tariro Makadzange, Tamsin Berry, and Dr Robert Madsen. It is fantastic to have both in-person and virtual attendees joining us today, and I hope the 'Always On' approach can offer a truly effective and impactful approach to future pandemic threats.

Enjoy all the Policy Summit has to offer!

Dr Elizabeth Kiss

Warden of Rhodes House & CEO of the Rhodes Trust

Welcome

from Philip Ma



Dear attendees,

Welcome to the inaugural Rhodes Policy Summit, which will consider how collectively we can strengthen our preparedness for the next pandemic. It is very much a question of 'when' not 'if' another pandemic will take place. Our global interconnectedness, as well as continued sharing of pathogens between humans and animals, and the impact of climate change on animal and human habitats and disease distribution all contribute to this ever-present risk.

We are now well positioned to take stock of the early days of the COVID-19 pandemic and reflect on what can and should be put in place now to allow us to be better prepared in future. With the Global Health Security Consortium as our knowledge partner, I am particularly excited that we are able to explore the potential of healthcare systems to be in a constant state of readiness for a new pandemic. This concept of being 'Always On' suggests that we should look at global health infrastructure with two purposes – how we can effectively improve routine healthcare delivery whilst being prepared to deliver a pandemic response effectively and at speed.

Applying this 'Always On' approach to vaccine delivery, for example, means thinking about new investments in regional vaccine

manufacturing capacity. We will need to consider how we establish infrastructure to produce life-course vaccines for diseases of public health significance, that can pivot when needed to produce vaccines against a new pandemic. As a global health concept, 'Always On' has as its foundation a motivation to create a more effective and equitable pandemic response and avoid the devastating impact that we saw during COVID-19 when many parts of the world were unable to access life-saving technologies.

I hope that by this end of the Policy Summit, we will have outlined a series of initiatives that explore applying this 'Always On' concept to pathogen surveillance, digital infrastructure, vaccine delivery and clinical research infrastructure. With our audience of global health and policy leaders, I am confident that we will be able to make progress on this ambitious agenda.

More broadly, I hope that as this Summit brings together experts from different areas of expertise and regions of the world, we will find fruitful opportunities to connect and to build new relationships and communities. Do be bold in imagining what could be possible, and thank you for giving your energy and ideas to this hugely important Summit.

Philip Ma

CEO and Founder, PrognomiQ, Inc.
Policy Summit advisory board member
and program supporter



Rhodes Policy Summit 2023

CREATING A POSITIVE LEGACY FROM THE PANDEMIC

PROGRAMME

| | | | |
|-------|--|--|--|
| 09:00 | Refreshments, Check-in and Mingle | | |
| 10:00 | Welcome and Introduction to the 'Always On' agenda for the Summit Professor Sir John Bell <i>Alberta & Magdalen 1975</i> Regius Professor of Medicine, University of Oxford & Chair of the Rhodes Trustees | | |
| 10:15 | Geopolitics and the COVID-19 pandemic response: How do we keep political attention and drive action on the Pandemic Prevention agenda? Tony Blair Executive Chairman, the Tony Blair Institute for Global Change and Former Prime Minister of Great Britain and Northern Ireland | | |
| 10:30 | Pandemic Reflections: Perspectives on the early days of COVID-19 <div>Dr Jessica Davis Associate Research Scientist, Northeastern University Professor George Fu Gao Professor, Chinese Center for Disease Control and Prevention</div> <div>Dr Merawi Aragaw Tegegne Head of Division for Health Emergency Preparedness and Response, Africa CDC Professor Ngaire Woods <i>New Zealand & Balliol 1987</i> Dean, Blavatnik School of Government, University of Oxford</div> <div>Moderator: Helene-Mari van der Westhuizen <i>Paul Roos Gymnasium, Stellenbosch & Green Templeton 2018</i> Global Health Fellow, Rhodes Trust & Global Health Security</div> | | |
| 11:30 | Comfort Break | | |
| 11:45 | Pandemic forecasting modelling: How would the world fare with a new pandemic today? Rasmus Bech Hansen CEO, Airfinity | | |

| | | | |
|-------|--|---|--|
| 12:15 | Developing solutions: What does an 'Always On' approach look like? | | |
| | Dr David Agus Founding Director and CEO, The Lawrence J. Ellison Institute for Transformative Medicine | Dr Lynda Stuart Executive Director of the Institute for Protein Design, University of Washington's School of Medicine | |
| | Professor Prabhat Jha <i>Prairies & Magdalen 1987</i> Professor of Global Health, University of Toronto | Moderator: Professor Dame Anna Dominiczak Regius Chair of Medicine, University of Glasgow & Chief Scientist (Health), Scottish Government | |
| 13:00 | Break for Lunch - Riverside Room | | |
| 14:00 | Parallel breakout room discussions: | | |
| | KELVIN | HASLETT | FLOWERS |
| | Strengthening global clinical research infrastructure for use during peacetime and pandemics Dr Tariro Makadzange <i>Prairies & Magdalen 1987</i> Founder and CEO, CRMG and Mutala Trust Dr Trevor Mundel President of Global Health, Bill & Melinda Gates Foundation Dr Amadou Sall Director, Institute Pasteur, Senegal Moderator: Tamsin Berry Co-Founder and Partner, Population Health Partners | Supporting public trust in science and pandemic policy delivery Sarah Hess Health Emergencies Programme, World Health Organization Mia Malan Editor-in-Chief, Bhekisisa Centre for Health Journalism Dr Tanvi Rai Health inequalities researcher, Oxford University Eloise Todd Executive Director & Co-Founder, Pandemic Action Network Moderator: Emily Stanger Sfeile Executive Director, Strategic Partnerships and Initiatives, Tony Blair Institute | Market shaping to support access to essential pandemic tools Hala Audi CEO, Unizima Dr Sergio Carmona Chief Medical Officer, Find Dr Richard Hatchett CEO, CEPI Dr Zhi Yang Chairman, BVCF Investment Fund Moderator: Dr Gabriel Seidman Director of Policy, The Lawrence J. Ellison Intsitute for Transformative Medicine |
| 15:30 | Comfort Break | | |
| 16:00 | Closing Plenary Outlining key 'Always On' missions and an agenda for further action | | |
| | Dr Hannah Kettler Director (Acting) for COVAX Design & Operationalisation, Gavi Professor Sir Andrew Pollard Professor of Paediatric Infection & Immunity, University of Oxford | Professor Glenda Gray President & CEO, South African Medical Research Council (SAMRC) Moderator: Hannah Kuchler Global Pharmaceutical Correspondent, <i>Financial Times</i> | |

Sessions



10:00 | KELVIN LECTURE THEATRE

Welcome and introducing the 'Always On' agenda for the Summit

Professor Sir John Bell

Alberta & Magdalen 1975

Regius Professor of Medicine, University of Oxford

A welcome to the Rhodes Policy Summit from the Chair of the Rhodes Trustees and Regius Professor of Medicine at Oxford University, Professor Sir John Bell (Alberta & Magdalen 1975).

10:15 | KELVIN LECTURE THEATRE

Geopolitics and the COVID-19 pandemic response:

How do we keep political attention and drive action on the Pandemic Prevention agenda?

Tony Blair

Executive Chairman, the Tony Blair Institute for Global Change, and
Former Prime Minister of Great Britain and Northern Ireland

When COVID-19 struck every nation was unprepared. Our ability to fight back came from the integrity of science and technology. But three years on we face some uncomfortable truths. As a global community we're still unprepared for the next pandemic.

And as memories begin to fade and new global pressures continue to grow, maintaining political and public focus on Pandemic Preparedness and Response (PPR) is becoming increasingly difficult.

In this keynote address, Tony Blair will set out how the creation of a new global health system that is 'Always On' will help to secure long-term political commitment and investment into PPR. By using key capabilities like digital infrastructure, disease surveillance and R&D and manufacturing infrastructure to improve everyday healthcare delivery, we can create an economically viable system that improves day-to-day patient care and remains ready to rapidly pivot to deliver an effective future pandemic response.

Because COVID-19 will not be the last pandemic threat we face, and we cannot afford to be unprepared again.

10:30 | KELVIN LECTURE THEATRE

Plenary Discussion:

Pandemic Reflections: Perspectives on the early days of COVID-19

Dr Jessica Davis

Associate Research Scientist,
Northeastern University

Professor George Fu Gao

Professor, Chinese Center for
Disease Control and Prevention

Dr Merawi Aragaw Tegegne

Head of Division for Health
Emergency Preparedness and
Response, Africa CDC

Professor Ngaire Woods

New Zealand & Balliol 1987
Dean of the Blavatnik School of
Government, University of Oxford

Moderator: Helene-Mari van der Westhuizen

*Paul Roos Gymnasium, Stellenbosch
& Green Templeton 2018*
Global Health Fellow, Rhodes
Trust & Global Health Security
Consortium

Panellists will share reflections on the early days of the COVID-19 pandemic. What can we infer about the inception of the COVID-19 pandemic from cryptic transmission? How do early policy responses compare across different countries? And what were the underlying reasons for the collective failure to fast-track access to life-saving technologies for the most vulnerable populations during this time of crisis?



11:45 | KELVIN LECTURE THEATRE

Pandemic forecasting modelling: How would the world fare with a new pandemic today?

Rasmus Bech Hansen

CEO, Airfinity

In this session we will look towards the future and consider the worst-case pandemic scenarios the world needs to be prepared for. With new modelling that considers different case fatality rates and transmissibility scenarios, this session will present multiple scenarios to prepare for and deliver a clear call for sustained political focus and investment from governments, global health organisations and industry into pandemic preparedness.

Plenary Discussion:

Developing solutions: what does an 'Always On' approach look like?

Dr David Agus

Founding Director and CEO, The Lawrence
J. Ellison Institute for Transformative Medicine

Dr Lynda Stuart

Executive Director of the Institute for Protein Design,
University of Washington's School of Medicine

Dr Prabhat Jha

Prairies & Magdalen 1987

Professor of Global Health, University of Toronto

Moderator:

Professor Dame Anna Dominiczak

Regius Chair of Medicine, University of Glasgow &
Chief Scientist (Health), Scottish Government

During the COVID-19 pandemic, essential infrastructure was lacking – including global digital infrastructure and distributed manufacturing capacity to support large-scale access to vaccination, therapeutics and diagnostics. Although some of these vital capacities did eventually catch up with the surge in demand, time and lives were lost because of the stop-start nature of the response. This gap is avoidable: knowing that it is feasible to ramp up certain capacities within the short term, we must ensure a seamless transition from routine healthcare to pandemic preparedness by focusing on the long-term, standing capacities that are otherwise difficult to develop. This is the rationale for the 'Always On' approach: it considers what has been developed for the COVID-19 pandemic, and its application to routine healthcare delivery, to ensure vital pandemic response infrastructure remains economically viable and ready to respond to the next global health crisis. Our panellists will discuss how this sustainability must also be linked to more equitable access to essential pandemic response tools.

FOLLOW THE CONVERSATION:

#PandemicPolicySummit



Parallel breakout room discussions:

Mapping 'Always On' solutions for future pandemics through three deep dives

14:00 | KELVIN

Strengthening global clinical research infrastructure for use during peacetime and pandemics

Dr Tariro Makadzange
Founder and CEO, CRMG and Mutala Trust

Dr Amadou Sall
CEO, Institut Pasteur, Senegal

Dr Trevor Mundel
President of Global Health,
Bill & Melinda Gates Foundation

Moderator: Tamsin Berry
Co-Founder and Partner,
Population Health Partners

COVID-19 highlighted the vital role clinical research plays. Innovative platform trials demonstrated the efficacy of treatments and the rapid delivery of vaccine trials resulting in the fastest development, regulatory approval and rollout of vaccines in history – saving millions of lives. However, clinical research capacity remains overly concentrated in high-income countries. During this policy deep dive, we will focus on how to support the development of sustainable clinical research capacity in low- and middle-income countries, as part of essential pandemic preparedness infrastructure.

14:00 | HASLETT

Supporting public trust in science and pandemic policy delivery

Mia Malan
Editor-in-Chief,
Bhekisa Centre for Health Journalism

Sarah Hess
Health Emergencies Programme,
World Health Organization

Dr Tanvi Rai
Senior Researcher, University of Oxford

Moderator: Emily Stanger Sfeile
Executive Director, Strategic Partnerships and
Initiatives, Tony Blair Institute for Social Change

Eloise Todd
Executive Director & Co Founder,
Pandemic Action Network

Misinformation and mistrust in pandemic prevention policies played a major role in whether preventative measures for COVID-19 were used. In this session we will discuss the roots of mistrust in pandemic prevention policy and interventions and mechanisms for earning the trust of communities in the scientific process. We will also develop actionable steps to ensure we are better prepared to communicate effectively about future health risks.

Market shaping to support access to essential pandemic tools

Hala Audi

CEO, Unizima

Dr Sergio Carmona

Chief Medical Officer, FIND

Dr Richard Hatchett

CEO, CEPI

Dr Zhi Yang

Chairman, BVCF investment fund

Moderator: Dr Gabriel Seidman

Director of Policy, The Lawrence J. Ellison
Institute for Transformative Medicine

There has been a co-ordinated effort, particularly for vaccines, to develop distributed manufacturing capacity in response to gross failures in achieving equitable access to essential COVID-19 pandemic tools. A key question is how to make sure these investments are fully utilised in the interpandemic period. Economic models that support innovation and develop markets for vaccines, diagnostics and therapeutics in peacetime for other diseases of public health concern is one strategy. In this panel we will consider widespread use of distributed manufacturing capacity, and also look at key learnings from the COVID-19 pandemic about facilitating product pull-through and accelerated access to novel technologies.



Closing Plenary: Outlining key 'Always On' missions and an agenda for further action

Dr Hannah Kettler

Director (Acting) for COVAX Design & Operationalization, Gavi

Professor Sir Andrew Pollard

Professor of Paediatric Infection & Immunity, University of Oxford

Professor Glenda Gray

President & CEO, South African Medical Research Council (SAMRC)

Moderator: Hannah Kuchler

Global Pharmaceutical Correspondent, *Financial Times*

All countries were insufficiently prepared for the COVID-19 pandemic, at the cost of millions of lives and trillions of dollars. In closing, our panellists will discuss what needs to be put in place to move some of the key 'Always On' principles discussed during the Summit forward. This will include partnerships that will be needed, potential levers for action and resources to enable delivery.

FOLLOW THE CONVERSATION:

#PandemicPolicySummit

Our Speakers



Dr David Agus

*Founding Director and CEO,
The Lawrence J. Ellison Institute
for Transformative Medicine*



Dr David B. Agus is one of the world's leading doctors and pioneering biomedical researchers. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine and a professor of medicine and engineering at the University of Southern California. A medical oncologist, Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making healthcare decisions tailored to individual needs. An international leader in global health and approaches for personalised healthcare, David serves in leadership roles at the World Economic Forum and is co-chair of the Global Health Security Consortium.

Hala Audi

CEO, Unizima



Hala is the CEO of Unizima, part of Belgian life sciences group Univercells. Unizima is a biomanufacturing services and technology provider, providing the expertise and cutting-edge technology needed to enable sustainable production of biologics such as vaccines, monoclonal antibodies and insulin in emerging markets. Hala joined Unizima from a career in government and global public health, including heading the pioneering UK review on antimicrobial resistance, chaired by Jim O'Neill. She has also been a senior leader in the UK Treasury Department and the Infrastructure and Projects Authority where her role focused on modernising delivery of the government's major projects and portfolio including through modularised construction. Earlier in her career she was an international arbitration lawyer with US law firm Skadden, Arps in New York and London.

Professor Sir John Bell

Alberta & Magdalen 1975

*Regius Professor of Medicine,
University of Oxford*



Professor Sir John Bell GBE, FRS is Regius Professor of Medicine at Oxford University. President of the Academy of Medical Sciences (2006 to 2011); Chair, Office for the Strategic Coordination of Health Research until 2017; Chair, Rhodes Trust; UK Life Sciences Champion since 2011. Appointed Knight Grand Cross of the Order of the British Empire (GBE) in 2015 for services to medicine, medical research and the life science industry. Co-developed and wrote both 2017 UK Life Sciences Industrial Strategy and 2021 Life Sciences Vision providing recommendations to HM Government on ensuring the long-term success of the life sciences sector.

Tamsin Berry

Moderator

*Co-Founder and Partner,
Population Health Partners*



Tamsin has extensive experience in government and expertise in public policy. She led serology and prevalence studies for the Government at the start of the COVID-19 Pandemic and as the former Director of the UK government's Office for Life Sciences she worked with Professor Sir John Bell to write the UK's Life Sciences Industrial Strategy. This led to £3 billion of investment into UK biotech across a number of public and private partnership projects. Tamsin held a number of leadership positions in government, spanning policy, corporate and communications roles including at the Cabinet Office, Department of Health and Public Health England. She began her career in consultancy at Accenture.

Tony Blair

Executive Chairman, the Tony Blair Institute for Global Change and Former Prime Minister of Great Britain and Northern Ireland



The Rt Hon Tony Blair, former Prime Minister of Great Britain and Northern Ireland, Executive Chairman of the Tony Blair Institute for Global Change. Tony Blair served as Prime Minister of Great Britain and Northern Ireland from 1997 to 2007 – the only Labour leader in the party's 100-year history to win three consecutive elections.

During his time in Downing Street Tony Blair implemented a major domestic reform agenda. Through record investment and reform, the UK's education and healthcare sectors were transformed. The New Labour Government led by Tony implemented the largest hospital and school building programme since the creation of the UK's welfare state. Overall crime was reduced by a third, and the first ever national minimum wage was introduced. There was also transformational progress on human rights and equality

and all of this took place during a period of record economic growth and levels of employment.

As Prime Minister, Tony Blair was also a central figure on the global stage. He helped bring peace to Northern Ireland, securing the historic Good Friday Agreement in 1998. He was a passionate advocate of an interventionist foreign policy. Tony created the Department for International Development, tripled the UK's foreign aid to Africa, and introduced landmark legislation to tackle climate change.

Since leaving office Tony Blair has spent most of his time working on three areas: supporting governments to deliver effectively for their people, working for peace in the Middle East, and countering extremism. He established the Tony Blair Institute for Global Change to work on some of the most difficult challenges in the world today, believing that real leadership has never been more necessary or more difficult.

Dr Sergio Carmona

Chief Medical Officer, FIND



Sergio Carmona is a global health leader, an MD PhD specialising in pathology. Following a distinguished career at the University of Witwatersrand (Johannesburg), he joined FIND in 2019, and in 2021, became the Chief Medical Officer. At FIND he covers a wide R&D portfolio for priority diseases, including tuberculosis, malaria, hepatitis, NTDs, AMR and NCDs, including HPV testing for early screening of cervical cancer. He is motivated by improving access to affordable diagnostics in LMICs. On the emergence of the COVID-19 pandemic, FIND was named co-convenor of the Diagnostics Pillar of the Access to COVID-19 Tools (ACT) Accelerator, in which Dr Carmona has played an instrumental role. Prior to joining FIND, Dr Carmona spent over a decade at the National Health Laboratory Services in South Africa, where he focused on molecular diagnostics and treatment monitoring for HIV, EID, HIV drug resistance and associated co-infections.

Dr Jessica Davis

*Associate Research Scientist,
Northeastern University*



Jessica Davis is an Associate Research Scientist in the Laboratory for the Modeling of Biological and Socio-Technical Systems at Northeastern University. Her research combines network science methods with data-driven epidemic modeling to respond to emerging infectious disease outbreaks. Her work aims to inform public health policies and enhance preparedness for future outbreaks by bridging the gap between theory and practice. She received her PhD in Network Science from Northeastern University, where she investigated the impact of cryptic transmission and travel restrictions during the early stages of the COVID-19 pandemic.

Professor Dame Anna Dominiczak

Moderator

*Regius Chair of Medicine, University
of Glasgow & Chief Scientist
(Health), Scottish Government*



Professor Dominiczak is a world-leading cardiovascular scientist and clinical academic. She has published extensively in top peer-reviewed journals. Between 2010 and 2020 she was Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow. In March 2020, Anna led the establishment of Lighthouse Laboratory in Glasgow to provide rapid COVID-19 diagnostics, and then was asked to become Director of Laboratories at the UK Department of Health and Social Care to lead all 10 Lighthouse Laboratories across the UK, the role she fulfilled until 2022.

In July 2022 she was appointed as a Chief Scientist (Health) for the Scottish Government. She works with the Chief Scientist Office to formulate and implement research and innovation strategy with a focus on transformative innovations to improve health of Scottish communities.

Professor George Fu Gao

*Professor George Fu Gao,
Professor, Chinese Center for
Disease Control and Prevention*



Gao is the former director-general of China CDC (2017-2022) and former vice-president of the National Natural Science Foundation of China. He is a member (academician) of the Chinese Academy of Sciences (CAS), an international member of the US National Academy of Sciences (NAS), a foreign member of the UK Royal Society (RS), and a member of the German National Academy of Sciences Leopoldina. He is the director of WHO and a professor of the Institute of Microbiology, CAS. Gao has pioneered and made numerous significant original breakthroughs on the pathogenesis mechanisms and pathogen-host interaction of emerging infectious pathogens. His interests also include global public health and health strategy, and he is an advocate of international collaboration in global public health.

Professor Glenda Gray

*President and CEO, South African
Medical Research Council
(SAMRC)*



An NRF A1 rated scientist, CEO and President of the South African Medical Research Council (SAMRC), Professor Glenda Gray is a qualified paediatrician and co-founder of the internationally recognised Perinatal HIV Research Unit in Soweto, South Africa. Prior to her appointment at the SAMRC, she was the Executive Director of the Perinatal HIV Research Unit, an affiliate of Wits University. Glenda's global profile includes a role as Co-PI of the HIV Vaccine Trials Network (HVTN), an international collaboration for the development of HIV/AIDS prevention vaccines. She has served as a Protocol Co-Chair of the multi-country Ensemble Study investigating the single-dose Ad26.COV2.S vaccine as an emergency response intervention. She received South Africa's highest honour – the Order of Mapungubwe – for her pioneering research in PMTCT.

Rasmus Bech Hansen

CEO & Founder, Airfinity



Rasmus is a globally recognised expert on scientific information and knowledge dissemination. He spent his earlier career as a Fortune500 strategist. Rasmus is a strong believer in the power of accurate information and new ideas – he founded his first, short lived, newspaper at the age of 13 – a passion that drove him to found Airfinity. As CEO of Airfinity he is often quoted in leading media companies such as the *Financial Times*, Bloomberg and CNN. He is a board member of the newspaper group, Information.dk. Rasmus holds a BSc in Political Science, a MPA from Harvard University and is a recipient of the Crown Prince Frederic award for excellent scholarship. He lives in London.

Dr Richard Hatchett

CEO, CEPI



Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations, or CEPI – a global partnership that supports the swift development of and equitable access to new vaccines and other defences against infectious diseases with epidemic and pandemic potential. Dr Hatchett's and CEPI's plan is for the world to neutralize those pandemic threats with prescient investment in scientific R&D. Before taking on the CEPI leadership just after its launch in 2017, Dr Hatchett was Acting Director of the U.S. Biomedical Advanced Research and Development Authority (BARDA). He has also served under two U.S. Presidents – George W. Bush and Barack Obama – as Director of Medical Preparedness Policy on the Homeland and National Security Councils.

Sarah Hess

*Health Emergencies Programme,
World Health Organization*



A global public health expert, working for the World Health Organization since 2014, focusing on global health policy, multisectoral partnerships and communication and trust during crises. Her current portfolio includes building multisectoral partnerships for enhanced epidemic and pandemic preparedness and prevention, leading a multidisciplinary initiative to define and measure trust in the context of pandemics, and building an innovative digital solution to increase access to credible health information during high-impact public health events.

Professor Prabhat Jha

Prairies & Magdalen 1987

*Professor of Global Health,
University of Toronto*



Prabhat Jha is a Professor at the University of Toronto, Endowed Professor in Global Health and Epidemiology and Canada Research Chair at the Dalla Lana School of Public Health, and the founding Director of the Centre for Global Health Research at St. Michael's Hospital.

Professor Jha is the lead investigator of the Million Death Study in India, which quantifies the causes of premature mortality in over three million homes from 1998 to the present day. His publications on tobacco control have enabled a global treaty now signed by over 180 countries. He founded the Statistical Alliance for Vital Events, which focuses on reliable measurement of premature mortality worldwide.

Earlier, Professor Jha served in senior roles at the World Health Organization and the World Bank. He was made an Officer of the Order of Canada in 2012. Professor Jha holds an MD from the University of Manitoba and a DPhil from Oxford University, where he studied as a Rhodes Scholar.

Dr Hannah Kettler

*Director (Acting) for COVAX
Design & Operationalization,
Gavi, the Vaccine Alliance*



Dr Hannah Kettler is a global expert in corporate social innovation, and acting Director for COVAX Design and Operationalisation at Gavi, the Vaccine Alliance. She oversees the policy design and operationalization of the COVAX Facility and the establishment of a dedicated Health Security function to deepen Gavi's engagement in responding to outbreaks, epidemics and pandemics, building on Gavi's current role and experience. Previously, Dr Kettler worked as Director for Vaccine Financing and Partnerships at PATH and at the Bill & Melinda Gates Foundation, most recently as Head of Industry and Leadership Engagement. In this role, she managed the Gates-CEO Roundtable. Hannah is a recognised authority and published author on policy incentives and partnership models to mobilise corporate investment in global health. She has a PhD in Economics from the University of Notre Dame.

Hannah Kuchler

Moderator

*Global Pharmaceutical
Correspondent, Financial Times*



Hannah Kuchler is the global pharmaceuticals correspondent for the *Financial Times*, leading the business newspaper's coverage of the life sciences industry. She has reported on the COVID-19 pandemic, receiving an honourable mention at the Society for Advanced Business Editing and Writing awards for a feature she led on the Pfizer vaccine. In the US, Kuchler collaborated with PBS Frontline on a documentary about the opioids crisis, which was nominated for an Emmy and won a Loeb award. Before covering the life sciences industry, she was a technology correspondent in Silicon Valley. She has worked for the *FT* for thirteen years in London, Hong Kong, New York, and San Francisco.

Mia Malan

*Editor, Bhekisisa Centre
for Health Journalism*



Mia Malan is the founder and editor-in-chief of Bhekisisa. She has worked in newsrooms in Johannesburg, Nairobi and Washington, DC, winning more than 30 awards for her radio, print and television work. A former Knight International Journalism Fellow and a Reuters Institute Journalism Fellow, Mia speaks internationally about health issues in Africa and media sustainability in the Global South. Mia has published widely in books and academic journals, including the *Brown Journal of World Affairs* and the *Georgetown Journal of International Affairs*. She was a TEDx speaker on how COVID-19 changed news reporting and regularly moderates panels for high-level events.

Dr Tariro Makadzange

Zimbabwe & Balliol 1999

Founder and CEO, CRMG and Mutala Trust



Tariro Makadzange is a medical-social entrepreneur, infectious disease physician and viral immunologist. Her career has spanned academia and industry in Africa and the United States. She is founder and CEO of CRMG and Mutala Trust in Zimbabwe. CRMG is a research organisation focused on diversifying research by including Africa and Africans in clinical trials and understanding immunogenetics in African populations including antibody discovery research for infectious diseases. Mutala Trust is a non-profit research organisation that conducts public health and implementation science research in communicable and non-communicable diseases. She is also an Adjunct Assistant Professor in Clinical Medicine at Stanford University and Faculty Fellow at the Stanford Center for Innovation in Global Health.

Dr Trevor Mundel

*President of Global Health,
Bill & Melinda Gates Foundation*



Trevor Mundel leads the foundation's efforts to develop high-impact interventions to drive down the global burden of infectious diseases. He manages the foundation's disease-specific R&D investments in malaria, HIV, tuberculosis, pneumococcal disease, enteric and diarrheal diseases and neglected tropical diseases. He also manages cross-cutting product development programmes, including Discovery & Translational Sciences, diagnostic tools, Integrated Development, the Institute for Disease Modeling, and vaccine development. This work relies on close collaboration with a global network of grantees and partners. In 2018, Trevor spearheaded the creation of the Bill & Melinda Gates Medical Research Institute to address a critical gap facing the development of novel biomedical interventions for diseases that disproportionately impact those with the greatest need. Trevor was also responsible for leading the foundation's early efforts to support the development of diagnostics, therapeutics, and vaccines for the global response to the COVID-19 pandemic.

Professor Sir Andrew Pollard

Director, Oxford Vaccine group



Sir Andrew is the Ashall Professor of Paediatric Infection and Immunity based within the Department of Paediatrics at the University of Oxford. He is the Director of the Oxford Vaccine Group and an honorary consultant Paediatrician at Oxford Children's Hospital. He received a knighthood in the Queen's Birthday Honours in 2021 for services to Public Health, especially in the pandemic, and the James Spence Medal in 2022. He along with the Oxford Vaccine Team were awarded the Copley Medal in 2023.

Dr Tanvi Rai

*Senior Researcher,
University of Oxford*



Tanvi Rai is a Senior Researcher in the Nuffield Department of Primary Care Health Sciences at the University of Oxford. Her research focuses on the social determinants of health and health inequalities, and explores how historically-informed and reflexive approaches that account for the structural and material realities of different populations, as well as the positionality of researchers in the generation of new knowledge, can lead to more robust and relevant health research.

Dr Amadou Sall

CEO, Institut Pasteur, Senegal



Dr Amadou A. Sall is the CEO of Institut Pasteur de Dakar in Senegal and director of the WHO collaborating center for Arboviruses and viral hemorrhagic fever. He has been chairman of the Global Outbreak Alert and Response Network and a member of the Coalition for Epidemic Preparedness and Innovation (CEPI) Scientific Advisory Board. Dr Sall is a virologist with a PhD in Public Health. He is an expert in epidemics response and control more specifically for arboviruses and viral hemorrhagic fevers (Ebola, Zika, Yellow Fever...) and high consequence pathogens. Dr Sall is a member of several expert committees for WHO (GOARN, TDR, SAGE, STAG-IH...) and OIE. Dr Sall is the co-chair of the COVID 19 laboratory technical working group of Africa CDC and member of the Africa Union AFTCOR steering Committee as well as the Senegalese Committee for COVID-19. He is the chairman of the Pasteur Network.

Dr Gabriel Seidman

Moderator

Director of Policy, The Lawrence J. Ellison Institute for Transformative Medicine



Dr Gabriel Seidman leads the global and domestic public health work at the Ellison Institute and its partnership with the Global Health Security Consortium. He has lived and worked on public health issues with governments across Africa and with multilateral global health organisations, including the World Bank and the Global Fund. His research and work focuses on global governance for systems strengthening and digital tools to improve health outcomes. Gabriel holds a Doctorate of Public Health from Harvard T. H. Chan School of Public Health.

Emily Stanger Sfeile

Moderator

Executive Director, Strategic Partnerships and Initiatives, Tony Blair Institute for Social Change



Emily Stanger Sfeile is Executive Director, Strategic Partnerships and Initiatives. She drives the strategy and delivery of partnerships for the Institute, including TBI's flagship work connecting tech innovators and leaders under the Tomorrow Partnership. Emily has worked closely with Heads of State for fifteen years advising on economic and social policy. Early in her career she was named to the Forbes 30 under 30 list for law and policy. She holds a Master's in International Development from Harvard University and degrees in Economics and Theology.

Dr Lynda Stuart

Executive Director of the Institute for Protein Design, University of Washington's School of Medicine



Lynda Stuart, MD, PhD. Lynda Stuart is a scientist, doctor, and passionate advocate for healthcare as a human right. Until very recently was the VP for Infectious disease at BioNTech but is leaving to pursue a senior leadership role at the University of Washington's School of Medicine as the Executive Director of the Institute for Protein Design. She earned a PhD from the University of Edinburgh and an MD from the University of Cambridge and the University of London. Dr. Stuart has served on the Massachusetts General Hospital Executive Committee for Research and as an affiliate of the Broad Institute of Harvard and MIT. As the Deputy Director for Vaccines & Human Immunology at the Bill & Melinda Gates Foundation, she led a team that aims to source novel approaches and accelerate the discovery, development, and translation of new passive and active immunisation strategies for foundation priority diseases.

Dr Merawi Aragaw Tegegne

Head of Division for Health Emergency Preparedness and Response, Africa CDC



Dr. Merawi Aragaw Tegegne is Medical Epidemiologist and Head of Emergency Preparedness and Response Division at the Africa Centres for Disease Control and Prevention (Africa CDC). He has over fifteen years of experience in public health emergency and disaster risk management. He leads the establishment and operations of the Africa CDC rapid response surge capacities - the African Volunteer Health Corps. He's a pioneer in the establishment of the Africa CDC; and served as a member of the multi-national expert committee of the African Union for the establishment of Africa CDC in 2014-2016. Prior to his current post, Merawi served as Advisor to the Minister of Health of Ethiopia on public health emergency management for more than 6 years. He led and participated in different disease outbreak investigations and responses both nationally and internationally.

Eloise Todd

*Executive Director & Co Founder,
Pandemic Action Network*



Eloise Todd is a co-founder of Pandemic Action Network and an advocacy, policy, campaigns and strategy specialist. She has over 20 years' experience working to change legislation and budgets to improve lives. Primarily, she has worked in international development and global health, including as a political adviser within EU institutions and as Global Policy Director of the ONE Campaign. Eloise campaigned against the UK's Brexit deal, founding and building a pro-European organisation, Best for Britain, into a national campaign force. Eloise Co-founded Pandemic Action Network with 3 colleagues in April 2020, and took on the Executive Director role in August 2022. The Network fights to prevent future outbreaks becoming pandemics, and to work for equity in all areas of pandemic prevention, preparedness and response.

Helene-Mari van der Westhuizen

*Paul Roos Gymnasium, Stellenbosch
& Green Templeton 2018*

*Global Health Fellow, Rhodes
Trust & Global Health Security
Consortium*



Dr Helene-Mari van der Westhuizen is a public health researcher and Fellow in Global Health with the Rhodes Trust and Global Health Security Consortium. She co-convenes postgraduate global health teaching at Oxford University. After training as a medical doctor in South Africa and working in the rural Eastern Cape, Helene-Mari completed her doctoral research at Oxford University funded by a Rhodes scholarship. Her research and evidence reviews on Tuberculosis and COVID-19 prevention have been relied on for national and international policy, and includes consultancy work for the World Health Organisation on infection control and TB diagnostics. Helene-Mari is passionate about science communication and has translated her research in live television interviews with the BBC and South African news, with her work featured in Nature and The Washington Post.

Professor Ngaire Woods

New Zealand & Balliol 1987

*Dean of the Blavatnik School of
Government, University of Oxford*



Professor Ngaire Woods is the founding Dean of the Blavatnik School of Government and Professor of Global Economic Governance at Oxford University. Her research focuses on how to enhance the governance of organisations, the challenges of globalisation, global development, and the role of international institutions and global economic governance.

She founded the Global Economic Governance Programme at Oxford University, and co-founded (with Robert O. Keohane) the Oxford-Princeton Global Leaders Fellowship programme. She led the creation of the Blavatnik School of Government.

Dr Zhi Yang

*Founder & Managing Partner,
BVCF*



Dr Yang founded BVCF in 2005. He has over 20 years of China and US life sciences investment experience as a private equity investor, senior executive, entrepreneur and scientific inventor. As private equity investor, he has built portfolios of over 30 companies, with eight exits (4 IPO and 4 acquisitions). As entrepreneur, he co-founded seven companies, six of which continue to conduct business and grow. As scientist, he was the principal inventor of more than 10 US and international patents, which have been documented to have earned MNCs over \$250 million. He was a senior fellow and faculty member at Rockefeller University and is now an advisor to the China Health and Medical Development Foundation, under China Ministry of Health. Dr Yang earned his PhD in Molecular Biology and Biochemistry at Harvard University as a fellow of CUSBEA first class, the first group of mainland Chinese biology scholars selected to be brought to the US after China opened its doors in 1979.

USEFUL INFORMATION

COVID-19

Should you have symptoms of a respiratory illness, or feel more comfortable attending group gatherings wearing respiratory protection – please feel free to use the masks provided at the registration desk. Please consider doing a lateral flow test in advance of the event, and if you test positive for COVID-19, we encourage you to join the Policy Summit online instead. The details to join online will be available on the conferencing app.

Name Badges

Please wear your name badge at all times – you will not be permitted access to the sessions in person without it. Staff members and volunteers can be identified by the label on their badges.

Wi-fi

There is public access Wifi available at the venue.

Dress Code

Business casual, no tie.
A self-manned cloakroom will be available near the registration desk.

Catering

If you have let us know about a specific dietary requirement and do not see something suitable being served at a meal, please do speak to a member of the catering team directly to receive your alternative option. Lunch and refreshments will be provided at the venue. Please bring your own bottle for drinking water: refill stations will be available throughout the venue.

Photography/ Livestreaming

A photographer and videographer will be present throughout the day and all sessions will be streamed for our online audience. Most of the sessions will also be recorded for viewing after the event. Please contact us in advance at conferences@rhodeshouse.ox.ac.uk if you have any questions regarding this. If you indicated during registration that you would not like to be photographed, you will be given a white lanyard upon arrival.

Social Media

We highly encourage you to join the conversation on social media using the hashtag #PandemicPolicySummit. Rhodes Trust can be found on Facebook as @RhodesTrust, on Instagram as @rhodestrust and on Twitter as @rhodes_trust

Parking

We cannot guarantee any parking spots and therefore do not recommend arriving that way. Uber, Bolt and similar ride-sharing apps are available across London as well as classic Hackney Cabs. The nearest Tube stations are Embankment, Charing Cross and Temple, all within a ten-minute walk to the venue. We recommend using Google Maps, TfL, Go, or CityMapper to plan your journey.

FOLLOW THE CONVERSATION:

#PandemicPolicySummit

SPECIAL THANKS TO...

Rhodes Trust:

Sorina Campean

Susanna Griffiths

Richard Hughes

Pema l'Anson

Babette Littlemore

Ben Russell

Tiffany Taylor

Georgie Thurston

Helene-Mari van der Westhuizen

*Paul Roos Gymnasium, Stellenbosch
& Green Templeton 2018*

Rachel Wood

Debbie Wray

Advisory Board:

Professor Sir John Bell

Alberta & Magdalen 1975

Tamsin Berry

Philip Ma

*Saskatchewan &
University 1986*

Robert Madsen

Utah & Trinity 1985

Tariro Makadzange

Zimbabwe & Balliol 1999

Trevor Mundel

*South Africa-at-Large &
Balliol 1984*

Global Health Security Consortium:

Dr David Agus

Megan Akodu

John Bell

Alberta & Magdalen 1975

Tamsin Berry

Prachetas Bhatnagar

Tony Blair

Paul Blakeley

Henry Li

Romina Mariano

South Africa-at-Large & Queen's 2016

Jay Sadanandan

Gabriel Seidman

Emily Stanger-Sfeile

Helene-Mari van der Westhuizen

*Paul Roos Gymnasium, Stellenbosch
& Green Templeton 2018*

Rhodes Scholar In Residence Working Group:

Nina Acharya

Ontario & Somerville 2020

Carina Hong

China & Hertford 2022

Jesse Lafontaine

Prairies & Jesus 2022

Rachel Leung

*Hong Kong & Green
Templeton 2021*

Varad Puntambekar

India & Green Templeton 2022

The 2023 Rhodes Global Policy Summit is made possible by the generous leadership support of Philip and Margaret Ma



Rhodes House, South Parks Road, Oxford OX1 3RG, United Kingdom

Tel: +44 (0)1865 270918 Email: conferences@rhodeshouse.ox.ac.uk

Web: www.rhodeshouse.ox.ac.uk



Rhodes Trust



@RhodesTrust



@rhodestrust



@rhodes_trust



Rhodes Trust

